A high-content blended peptide system for advanced metabolic research

CagriTirz 70 mg from SEMPICA HEALTHCARE is a combined research peptide formulation, supplied as a pre-mixed liquid in a sealed pen format. It brings together two well-studied compounds in a single research material for laboratories exploring complex metabolic signalling behaviour.

This product is sold strictly for research and development purposes only. It is not a medicine, not a treatment, and no instructions, protocols, or advice are provided. The purchaser accepts full responsibility for how the product is handled and used within their own research environment.

What CagriTirz Is, in Plain Terms

CagriTirz is a blended research system containing:

• Tirzepatide – 60 mg
• Cagrilinitide – 10 mg

Researchers use blends like this when they want to study how different signalling mechanisms behave together, rather than examining each compound on its own. In simple terms, it allows observation of interaction, overlap, and persistence across more than one signalling pathway at the same time.

Why This Blend Exists

Tirzepatide and Cagrilinitide have each been widely examined in metabolic research. When combined, they allow researchers to explore questions such as:

• How long-acting and shorter-acting signals influence each other
• Whether combined signalling changes overall signal duration
• How pathway strength behaves when compounds are paired
• How blended systems compare to single-compound models

This type of work is common in comparative and exploratory research, where understanding relationships matters more than outcomes.

Research Background and Interest

Both compounds included in CagriTirz have appeared in high-profile metabolic and weight-related research, with published studies reporting exceptionally strong results, including average body-weight reductions of around 20% or more in study participants over extended periods.

These figures are widely cited and help explain why blended systems like CagriTirz attract attention in research.

To be clear:

• These results come from external studies
• They are not linked to this product
• No outcomes are promised or implied
• This product is not sold for weight loss or treatment

Why a 70 mg Format Is Used

The 70 mg CagriTirz format is typically chosen for:

• Extended observation studies
• Repeat analysis without replacing materials
• Comparative work across multiple conditions
• Research where continuity matters

A higher-content format reduces interruptions and helps maintain consistency within a single study.

How This Product Is Supplied

SEMPICA HEALTHCARE supplies CagriTirz 70 mg as:

• A laboratory-prepared liquid blend
• Pre-mixed in 3 ml bacteriostatic water
• Sealed in a pen format for controlled handling
• Clearly labelled with known composition

This removes the need for manual mixing and avoids variability introduced during preparation.

Composition and Technical Details

Product name: CagriTirz
Total peptide content: 70 mg

Composition:
• Tirzepatide – 60 mg
• Cagrilinitide – 10 mg

Category: Multi-pathway regulatory peptide research blend
Purity: ≥ 99% (each component)

Solvent: 3 ml bacteriostatic water
Appearance: Clear liquid
Solution colour: Clear
Format: Factory-sealed research pen

This information is provided so buyers know exactly what the product contains.

What You Receive

Each CagriTirz 70 mg Research Pen includes:

• One pre-mixed CagriTirz 70 mg research pen
• Individually sealed microneedles (research handling only)
• Alcohol swabs
• Printed storage and preservation notes

No instructions, dosing guidance, or research protocols are supplied.

Storage and Preservation

• Store refrigerated when not in use
• Do not freeze
• Protect from light and UV exposure
• Keep sealed when not being handled
• Inspect visually; the solution should remain clear

These notes exist only to help preserve material integrity.

Use Alongside Other Research Materials

Some researchers choose to purchase CagriTirz alongside other peptides to expand comparative analysis, such as MOTS-C, AOD-9604, SS-31, Retatrutide, or GHK-CU.

SEMPICA HEALTHCARE does not recommend combinations or provide guidance. All decisions remain with the purchaser.

About SEMPICA HEALTHCARE

Many peptide sellers focus on quick sales of single vials with minimal explanation. SEMPICA HEALTHCARE focuses on clearly defined research materials, prepared in advance and described in plain language.

We supply the product.
Responsibility for its use rests entirely with you.

Important Research Use Notice

This product is supplied strictly for research and development purposes only.

It is not intended to:

• Diagnose, treat, cure, or prevent any disease
• Be used on or by humans or animals
• Be represented as a medicine, supplement, or injectable product

SEMPICA HEALTHCARE provides no guidance, plans, protocols, or advice beyond the information published here. By purchasing, you confirm that you accept full responsibility for use, storage, handling, and regulatory compliance.

Buy CagriTirz 70 mg Research Pen